194 related articles for article (PubMed ID: 28651304)
1. Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study.
Lim YL; Kim MY; Jang YO; Baik SK; Kwon SO
Gut Liver; 2017 Sep; 11(5):702-710. PubMed ID: 28651304
[TBL] [Abstract][Full Text] [Related]
2. Effect of poorly absorbable antibiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and meta-analysis.
Mendoza YP; Rodrigues SG; Bosch J; Berzigotti A
Dig Liver Dis; 2020 Sep; 52(9):958-965. PubMed ID: 32736898
[TBL] [Abstract][Full Text] [Related]
3. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study.
Bishnu S; Ahammed SM; Sarkar A; Hembram J; Chatterjee S; Das K; Dhali GK; Chowdhury A; Das K
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):54-59. PubMed ID: 29099421
[TBL] [Abstract][Full Text] [Related]
4. Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension.
Kim JH; Kim JM; Cho YZ; Na JH; Kim HS; Kim HA; Kang HW; Baik SK; Kwon SO; Cha SH; Kim YJ; Kim MY
Clin Mol Hepatol; 2014 Dec; 20(4):376-83. PubMed ID: 25548744
[TBL] [Abstract][Full Text] [Related]
5. 5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial.
Vukotic R; Di Donato R; Roncarati G; Simoni P; Renzulli M; Gitto S; Schepis F; Villa E; Berzigotti A; Bosch J; Andreone P
J Hepatol; 2023 Oct; 79(4):977-988. PubMed ID: 37482222
[TBL] [Abstract][Full Text] [Related]
6. Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity.
Baik SK; Park DH; Kim MY; Choi YJ; Kim HS; Lee DK; Kwon SO; Kim YJ; Park JW; Chang SJ
J Gastroenterol; 2003; 38(12):1150-4. PubMed ID: 14714252
[TBL] [Abstract][Full Text] [Related]
7. Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind study.
Schepke M; Wiest R; Flacke S; Heller J; Stoffel-Wagner B; Herold T; Ghauri M; Sauerbruch T
Am J Gastroenterol; 2008 May; 103(5):1152-8. PubMed ID: 18422814
[TBL] [Abstract][Full Text] [Related]
8. Comparative randomized study on efficacy of losartan versus propranolol in lowering portal pressure in decompensated chronic liver disease.
Agasti AK; Mahajan AU; Phadke AY; Nathani PJ; Sawant P
J Dig Dis; 2013 May; 14(5):266-71. PubMed ID: 23280243
[TBL] [Abstract][Full Text] [Related]
9. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis.
Lin HC; Yang YY; Hou MC; Huang YT; Lee FY; Lee SD
Am J Gastroenterol; 2004 Oct; 99(10):1953-8. PubMed ID: 15447755
[TBL] [Abstract][Full Text] [Related]
10. Combined administration of propranolol + AG490 offers better effects on portal hypertensive rats with cirrhosis.
Wang D; Wang Q; Yin J; Dong R; Wang Q; Du X; Lu J
J Gastroenterol Hepatol; 2016 May; 31(5):1037-44. PubMed ID: 26487394
[TBL] [Abstract][Full Text] [Related]
11. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
Garcia-Tsao G; Bosch J; Kayali Z; Harrison SA; Abdelmalek MF; Lawitz E; Satapathy SK; Ghabril M; Shiffman ML; Younes ZH; Thuluvath PJ; Berzigotti A; Albillos A; Robinson JM; Hagerty DT; Chan JL; Sanyal AJ;
J Hepatol; 2020 May; 72(5):885-895. PubMed ID: 31870950
[TBL] [Abstract][Full Text] [Related]
12. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.
Bañares R; Moitinho E; Piqueras B; Casado M; García-Pagán JC; de Diego A; Bosch J
Hepatology; 1999 Jul; 30(1):79-83. PubMed ID: 10385642
[TBL] [Abstract][Full Text] [Related]
13. A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis.
Kim SG; Kim TY; Sohn JH; Um SH; Seo YS; Baik SK; Kim MY; Jang JY; Jeong SW; Lee B; Kim YS; Suk KT; Kim DJ
Am J Gastroenterol; 2016 Nov; 111(11):1582-1590. PubMed ID: 27575713
[TBL] [Abstract][Full Text] [Related]
14. Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study.
Kim MY; Baik SK; Park DH; Lim DW; Kim JW; Kim HS; Kwon SO; Kim YJ; Chang SJ; Lee SS
Liver Int; 2007 Oct; 27(8):1103-10. PubMed ID: 17845539
[TBL] [Abstract][Full Text] [Related]
15. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis.
Bañares R; Moitinho E; Matilla A; García-Pagán JC; Lampreave JL; Piera C; Abraldes JG; De Diego A; Albillos A; Bosch J
Hepatology; 2002 Dec; 36(6):1367-73. PubMed ID: 12447861
[TBL] [Abstract][Full Text] [Related]
16. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis.
Reiberger T; Ferlitsch A; Payer BA; Mandorfer M; Heinisch BB; Hayden H; Lammert F; Trauner M; Peck-Radosavljevic M; Vogelsang H;
J Hepatol; 2013 May; 58(5):911-21. PubMed ID: 23262249
[TBL] [Abstract][Full Text] [Related]
17. Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial.
Kimer N; Pedersen JS; Tavenier J; Christensen JE; Busk TM; Hobolth L; Krag A; Al-Soud WA; Mortensen MS; Sørensen SJ; Møller S; Bendtsen F;
J Gastroenterol Hepatol; 2018 Jan; 33(1):307-314. PubMed ID: 28671712
[TBL] [Abstract][Full Text] [Related]
18. Propranolol treatment of portal hypertension in cirrhosis patients is better the higher the untreated pressure: a single-centre prospective experience.
Heebøll S; Villadsen GE; Aagaard NK; Grønbæk H; Vilstrup H; Keiding S
Scand J Gastroenterol; 2013 Aug; 48(8):969-73. PubMed ID: 23755897
[TBL] [Abstract][Full Text] [Related]
19. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial.
Pose E; Napoleone L; Amin A; Campion D; Jimenez C; Piano S; Roux O; Uschner FE; de Wit K; Zaccherini G; Alessandria C; Angeli P; Bernardi M; Beuers U; Caraceni P; Durand F; Mookerjee RP; Trebicka J; Vargas V; Andrade RJ; Carol M; Pich J; Ferrero J; Domenech G; Llopis M; Torres F; Kamath PS; Abraldes JG; Solà E; Ginès P
Lancet Gastroenterol Hepatol; 2020 Jan; 5(1):31-41. PubMed ID: 31607677
[TBL] [Abstract][Full Text] [Related]
20. Octreotide enhances portal pressure reduction induced by propranolol in cirrhosis: a randomized, controlled trial.
Vorobioff JD; Ferretti SE; Zangroniz P; Gamen M; Picabea E; Bessone FO; Reggiardo V; Diez AR; Tanno M; Cuesta C; Tanno HE
Am J Gastroenterol; 2007 Oct; 102(10):2206-13. PubMed ID: 17608776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
